Irregular nucleoside dimer phosphoramidite and synthesis method thereof
By removing acetyl or benzoyl groups under ammonia water conditions and condensation, the heteromorphic nucleoside dimer phosphoramidite was successfully synthesized, solving the impurity control problem during the polymerization of oligonucleotides and providing oligonuclear A platform for lytic impurity series research and new product development simplifies the synthesis route and improves the feasibility of impurity analysis.
Patent Information
- Application Number
- CN202410825308.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-24
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively control the index changes of impurities during polymerization of oligonucleotide drugs, which leads to difficulty in controlling purity and lacks methods suitable for analysis and synthesis of impurities such as dimers, trimers, tetramers, etc.
It proposes a heteromorphic nucleoside dimer phosphoramidite and its synthesis method. By removing acetyl or benzoyl groups under ammonia water conditions, condensation is used to obtain heteromorphic nucleoside dimer phosphoramidite to ensure the intermediate Stability and purity, and provide ideas for other types of polymer impurities analysis.
The discovery of new substances of heteromorphic nucleoside dimer phosphoramidite has been achieved, providing a platform for the series of oligonucleotide impurities and the development of new products, broadening the scope of oligonucleotides, simplifying the synthesis route, and suitable for large-scale Large-scale production and improve the feasibility of impurity analysis.
Smart Images

Figure CN118909015A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of chemical synthesis of oligonucleosides and nucleotides, and in particular to a heteromorphic nucleoside dimer phosphoramidite and a synthesis method thereof. Background Art
[0002] Small nucleic acid drugs are currently the third wave of drugs emerging in the world after small molecule drugs and antibody drugs. Among them, oligonucleotide drugs are widely favored by the global biopharmaceutical community for their unique therapeutic effects. As oligonucleotide drugs continue to grow, their production processes are also maturing. At present, major pharmaceutical companies mainly produce oligonucleotide drugs by solid phase method and liquid phase method. From the perspective of the availability and operability of monomer structural units, developing a molecular building block from dimers, trimers, tetramers, and pentamers is an idea to optimize the current process.
[0003] At present, there are patents and literatures reporting some methods for synthesizing dimers, trimers, tetramers, and pentamers of nucleotides, such as CN114230624, etc. However, since oligonucleotide drugs are gene drugs, impurities will change exponentially during the polymerization process, and purity needs to be strictly controlled.
[0004] Therefore, providing a method that can provide ideas for impurity analysis and provide ideas for analysis and synthesis of other types of impurities such as dimers, trimers, tetramers, pentamers, etc. is an issue that needs to be solved urgently. Summary of the invention
[0005] In view of this, the present application proposes a heteromorphic nucleoside dimer phosphoramidite and a synthesis method thereof to solve the above problems.
[0006] According to one aspect of the present application, a heteromorphic nucleoside dimer phosphoramidite is provided, wherein the structure of the heteromorphic nucleoside dimer phosphoramidite is as shown in Formula I;
[0007] Formula I:
[0008]
[0009] Wherein, R1 and R2 are any one of the protecting groups selected from H, OTBS, OMe, OMOE or F;
[0010] B1 is any one of adenine base, cytosine base or 5-methylcytosine base;
[0011] B2 is any one of acetyl-protected adenine base AAc, benzoyl-protected adenine base ABz, isobutyryl-protected guanine base GiBu, thymine base T, acetyl-protected cytosine base CAc, or benzoyl-protected cytosine base CBz.
[0012] According to another aspect of the present application, a method for synthesizing a heteromorphic nucleoside dimer phosphoramidite is provided, which is used to synthesize the heteromorphic nucleoside dimer phosphoramidite according to claim 1, comprising the following steps:
[0013] Using the compound of formula II as a raw material, removing the acetyl group Ac or the benzoyl group Bz under ammonia conditions to synthesize the intermediate III;
[0014] Using the intermediate III and the compound of formula IV as raw materials, condensing with a condensing agent to obtain a heteromorphic nucleoside dimer phosphoramidite;
[0015] Formula II:
[0016]
[0017] Intermediate III:
[0018]
[0019] Formula IV:
[0020]
[0021] The reaction formula is as follows:
[0022]
[0023] In a possible implementation, the method of synthesizing intermediate III by removing acetyl group Ac or benzoyl group Bz under ammonia conditions using the compound of formula II as a raw material comprises:
[0024] Using the compound of formula II as a raw material, and dissolving it in a first preset volume of a first solvent to obtain a first solution;
[0025] The first solution is cooled under nitrogen protection, and a first preset amount of concentrated aqueous ammonia is added dropwise to react. After the reaction is completed, it is purified by a silica gel column to obtain an intermediate III.
[0026] In a possible implementation, the intermediate III and the compound of formula IV are used as raw materials, and condensed with a condensing agent to obtain a heteromorphic nucleoside dimer phosphoramidite, comprising:
[0027] Dissolving the intermediate III and the compound of formula IV in a second preset volume of a second solvent to obtain a second solution;
[0028] The second solution is cooled under nitrogen protection, and a second preset amount of condensing agent is added to react, and after the reaction is completed, extraction is performed using a sodium bicarbonate solution;
[0029] The extract was concentrated to dryness and then purified by silica gel column to obtain heteromorphic nucleoside dimer phosphoramidite.
[0030] In a possible implementation, the second solution is cooled under nitrogen protection, and a second preset amount of condensing agent is added to react, and after the reaction is completed, extraction is performed using a sodium bicarbonate solution, comprising:
[0031] The second solution is protected under nitrogen, cooled to -20°C-5°C, and a second preset amount of condensing agent is added to react at a reaction temperature of 25°C;
[0032] After the reaction was completed, the mixture was extracted with a 5% by mass sodium bicarbonate solution.
[0033] In a possible implementation, the condensing agent is any one of tetrazole, ethyl tetrazole, benzyl tetrazole, 5-ethylthio tetrazole or cyanotetrazole, and the second preset amount is 0.5-1.5 equivalents.
[0034] In a possible implementation, the first solvent is any one of dichloromethane, tetrahydrofuran or acetonitrile, and the first preset volume is 5-12 times the volume of the compound of formula II.
[0035] In a possible implementation, the concentrated ammonia water is 25% ammonia water by mass, and the first preset amount is 3-10 equivalents of the compound of formula II.
[0036] In a possible implementation, the equivalent ratio of the intermediate III to the compound of formula IV is 1:1.
[0037] In a possible implementation manner, the second solvent is any one of dichloromethane, tetrahydrofuran or acetonitrile.
[0038] Beneficial effects of this application:
[0039] The present application provides a heteromorphic nucleoside dimer phosphoramidite and a synthesis method thereof, wherein the compound of formula II is used as a raw material, and the acetyl group Ac or the benzoyl group Bz is removed under ammonia conditions to synthesize the intermediate III; the intermediate III and the compound of formula IV are used as raw materials, and the heteromorphic nucleoside dimer phosphoramidite is obtained after condensation using a condensing agent. The heteromorphic nucleoside dimer phosphoramidite discovered in the present application belongs to a new substance, and there is no literature or patent report at present. The discovery of this substance provides a platform significance for the research of oligonucleotide impurity series and the development of new products, and broadens the scope of oligonucleotides. It should be particularly noted that the present application can ensure the stability of the phosphoramidite structure and remove the protecting group by using ammonia water in the process of synthesizing intermediate III, thereby ensuring the synthesis of intermediate III. In addition, the phosphoramidite raw materials II and IV of various bases involved in the present application are commercially available, easy to obtain, the overall synthesis route is short, the operation is simple, and it is suitable for large-scale production.
[0040] Other features and aspects of the present application will become apparent from the following detailed description of exemplary embodiments with reference to the attached drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate exemplary embodiments, features, and aspects of the present application and, together with the description, serve to explain the principles of the present application.
[0042] Figure 1 A flow chart showing the synthesis method of heteromorphic nucleoside dimer phosphoramidite according to an embodiment of the present application;
[0043] Figure 2 The high performance liquid chromatogram of the heteromorphic nucleoside dimer phosphoramidite of the embodiment of the present application is shown;
[0044] Figure 3 An automatically scaled chromatogram of heteromorphic nucleoside dimer phosphoramidites according to an example of the present application is shown. DETAILED DESCRIPTION
[0045] Various exemplary embodiments, features and aspects of the present application will be described in detail below with reference to the accompanying drawings. The same reference numerals in the accompanying drawings represent elements with the same or similar functions. Although various aspects of the embodiments are shown in the accompanying drawings, the drawings are not necessarily drawn to scale unless otherwise specified.
[0046] Among them, it should be understood that the terms "center", "longitudinal", "lateral", "length", "width", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside", "clockwise", "counterclockwise", "axial", "radial", "circumferential" and the like indicate orientations or positional relationships based on the orientations or positional relationships shown in the accompanying drawings, and are only for the convenience of describing the present application or simplifying the description, and do not indicate or imply that the referred device or element must have a specific orientation, be constructed and operated in a specific orientation, and therefore should not be understood as a limitation on the present application.
[0047] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of the features. In the description of this application, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.
[0048] The word “exemplary” is used exclusively herein to mean “serving as an example, example, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments.
[0049] In addition, in order to better illustrate the present application, numerous specific details are given in the following specific embodiments. It should be understood by those skilled in the art that the present application can also be implemented without certain specific details. In some examples, methods, means, components and circuits well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present application.
[0050] According to one aspect of the present application, a heteromorphic nucleoside dimer phosphoramidite is provided, and the structure of the heteromorphic nucleoside dimer phosphoramidite is shown in Formula I;
[0051] Formula I:
[0052]
[0053] Wherein, R1 and R2 are any one of the protecting groups selected from H, OTBS, OMe, OMOE or F;
[0054] B1 is any one of adenine base, cytosine base or 5-methylcytosine base;
[0055] B2 is any one of acetyl-protected adenine base AAc, benzoyl-protected adenine base ABz, isobutyryl-protected guanine base GiBu, thymine base T, acetyl-protected cytosine base CAc, or benzoyl-protected cytosine base CBz.
[0056] The heteronucleoside dimer phosphoramidite I provided in this application is a new substance, and there is no literature or patent reporting it. The discovery of this substance provides a platform for the research of oligonucleotide magazine series and the development of new products, and broadens the scope of oligonucleotides.
[0057] According to another aspect of the present application, a method for synthesizing a heteromorphic nucleoside dimer phosphoramidite is provided, which is used to synthesize the heteromorphic nucleoside dimer phosphoramidite of claim 1, comprising the following steps:
[0058] S100, using the compound of formula II as a raw material, removing the acetyl group Ac or the benzoyl group Bz in the presence of aqueous ammonia to synthesize an intermediate III;
[0059] S200, using intermediate III and compound of formula IV as raw materials, condensing with a condensing agent to obtain heteromorphic nucleoside dimer phosphoramidite;
[0060] Formula II:
[0061]
[0062] Intermediate III:
[0063]
[0064] Formula IV:
[0065]
[0066] The reaction formula is as follows:
[0067]
[0068] The preparation method of heteromorphic nucleoside dimer phosphoramidite I of the present application comprises two steps. That is, step S100 synthesizes intermediate III and step S200 synthesizes heteromorphic nucleoside dimer phosphoramidite I. Specifically, in the process of synthesizing intermediate III in step S100, acetyl Ac or benzoyl Bz is removed under ammonia conditions by using compound of formula II as raw material. In the process of synthesizing heteromorphic nucleoside dimer phosphoramidite I in step S200, heteromorphic nucleoside dimer phosphoramidite I is obtained by condensing intermediate III and compound of formula IV as raw materials with a selected condensing agent. It should be noted that the phosphoramidite raw materials II and IV of various bases involved in the present application are commercially available, simple and easy to obtain, the synthetic route is short, the operation is simple, and it is suitable for large-scale production. Since the phosphoramidite monomer itself has unstable characteristics such as easy oxidation and easy hydrolysis, the present invention adopts ammonia, which can not only ensure the stability of the phosphoramidite structure but also remove the protecting group, thereby ensuring the perfect synthesis of intermediate III. Among them, intermediate III is a new substance and there is no literature or patent reporting on it.
[0069] Figure 2 The HPLC chromatogram of the embodiment of the present application is shown, and the corresponding peak area percentage data are shown in Table 1.
[0070]
[0071]
[0072] Table 1 Peak area percentage data table Figure 3 The automatically scaled chromatogram of this embodiment is shown, and the corresponding results are shown in Table 2.
[0073]
[0074] Table 2. Parameters corresponding to automatic scaling of chromatograms
[0075] In a possible implementation, the compound of formula II is used as a raw material, and the acetyl group Ac or the benzoyl group Bz is removed under ammonia conditions to synthesize the intermediate III, including: using the compound of formula II as a raw material, and dissolving it in a first preset volume of a first solvent to obtain a first solution; cooling the first solution under nitrogen protection, and adding a first preset amount of concentrated ammonia water dropwise to react, and after the reaction is completed, purifying it through a silica gel column to obtain the intermediate III.
[0076] In a possible implementation, the condensing agent is any one of tetrazole, ethyl tetrazole, benzyl tetrazole, 5-ethylthio tetrazole or cyanotetrazole, and the second preset amount is 0.5-1.5 equivalents.
[0077] In a possible implementation, the first solvent is any one of dichloromethane, tetrahydrofuran or acetonitrile, and the first preset volume is 5-12 times the volume of the compound of formula II.
[0078] In a possible implementation, the concentrated aqueous ammonia is aqueous ammonia with a mass fraction of 25%, and the first preset amount is 3-10 equivalents of the compound of formula II.
[0079] It should be noted that before using ammonia to remove the acetyl Ac or benzoyl Bz to synthesize the intermediate III, it is necessary to first dissolve the raw material formula II compound in 5-12 times the volume of the first solvent to obtain a first solution. Wherein, the first solvent is any one of dichloromethane, tetrahydrofuran or acetonitrile. Subsequently, the first solution is cooled to -20°C-5°C under nitrogen protection, and 3-10 equivalents of 25% concentrated ammonia are added dropwise and reacted at -20°C-5°C for 0.5-2h. After the reaction at -20°C-5°C is completed, the concentrated dryness is directly purified by a silica gel column to obtain the intermediate III.
[0080] In a possible implementation, intermediate III and a compound of formula IV are used as raw materials, and a condensation agent is used to condense to obtain a heteromorphic nucleoside dimer phosphoramidite, comprising: dissolving intermediate III and a compound of formula IV in a second preset volume of a second solvent to obtain a second solution; cooling the second solution under nitrogen protection, and adding a second preset amount of a condensation agent to react, and extracting with a sodium bicarbonate solution after the reaction is completed; concentrating the extract to dryness, and purifying it through a silica gel column to obtain a heteromorphic nucleoside dimer phosphoramidite.
[0081] In a possible implementation, the second solution is cooled under nitrogen protection, and a second preset amount of condensing agent is added to react, and after the reaction is completed, sodium bicarbonate solution is used for extraction, including: the second solution is protected under nitrogen, cooled to -20°C-5°C, and a second preset amount of condensing agent is added to react, and the reaction temperature is 25°C; after the reaction is completed, sodium bicarbonate solution with a mass fraction of 5% is used for extraction.
[0082] In a possible implementation, the equivalent ratio of the intermediate III to the compound of formula IV is 1:1.
[0083] In a possible implementation manner, the second solvent is any one of dichloromethane, tetrahydrofuran or acetonitrile.
[0084] It should be noted that before preparing the heteromorphic nucleoside dimer phosphoramidite, 1.0 equivalent of intermediate III and 1.0 equivalent of compound IV are each taken and dissolved in a second solvent to obtain a second solution. Among them, the second solvent can be selected from dichloromethane, tetrahydrofuran, or acetonitrile. Subsequently, the second solution is cooled to -20°C-5°C under nitrogen protection, and 0.5-1.5 equivalents of a condensing agent are added. Among them, the condensing agent is any one of tetrazole, ethyl tetrazole, benzyl tetrazole, 5-ethylthio tetrazole or cyanotetrazole. After the reaction is completed at 25°C, a 5% sodium bicarbonate solution is used for extraction. After the extract is concentrated to dryness, it is directly purified by a silica gel column to obtain the heteromorphic nucleoside dimer phosphoramidite I. In the heteronucleoside dimer phosphoramidite I, R1 and R2 represent H, or OTBS, or Ome, or OMOE, or F and other protecting groups respectively; B1 represents an adenine base, or a cytosine base, or a 5-methylcytosine base; B2 represents an acetyl-protected adenine base AAc, or a benzoyl-protected adenine base ABz, or an isobutyryl-protected guanine base GiBu, or a thymine base T, or an acetyl-protected cytosine base CAc, or a benzoyl-protected cytosine base CBz.
[0085] The following is a detailed description of a method for synthesizing a heteromorphic nucleoside dimer phosphoramidite according to an embodiment of the present application.
[0086] Example 1: Synthesis of heteromorphic nucleoside dimer phosphoramidite I-1:
[0087]
[0088] The reaction formula is as follows:
[0089]
[0090] The first step of synthesis of III-1:
[0091] Take II-1 (10g, 1.0 equivalent) and dissolve it in acetonitrile (50mL, 5V), cool it down to -20℃ under nitrogen protection, add 25% concentrated ammonia (7.3g, 10 equivalents) dropwise, and react at -20℃ for 2h to complete the reaction. Concentrate and directly purify it on a silica gel column to obtain intermediate III-1 (4.2g, yield 47%). HPLC purity: 99.31%; MS [M+H] + : 884;
[0092] Step 2 Synthesis of I-1:
[0093] Take intermediate III-1 (4.0g, 1.0 equivalent) and IV-1 (4.1g, 1.0 equivalent) as raw materials and dissolve them in 80mL dichloromethane solvent. Cool the solution to 0°C under nitrogen protection, add tetrazole (158mg, 0.5 equivalent), and after the reaction is completed at 25°C, extract with 5% sodium bicarbonate solution. After the extract is concentrated to dryness, it is directly purified by silica gel column to obtain heteromorphic nucleoside dimer phosphoramidite I-1 (5g, 65% yield). HPLC purity: 99.66%; MS [M+H] + :1686.
[0094] Example 2: Synthesis of heteromorphic nucleoside dimer phosphoramidite I-2:
[0095]
[0096] The reaction formula is as follows:
[0097]
[0098] The first step of synthesis of III-2:
[0099] Take II-2 (10 g, 1.0 equivalent) and dissolve it in tetrahydrofuran (120 mL, 12 V), cool it down to 5 ° C under nitrogen protection, add 25% concentrated ammonia (4.6 g, 5 equivalents) dropwise, and react at 5 ° C for 0.5 h to complete the reaction. Concentrate and directly purify it on a silica gel column to obtain intermediate III-2 (5.9 g, yield 63%). HPLC purity: 98.87%; MS [M + H] +: 730;
[0100] Step 2 Synthesis of I-2: Take intermediate III-2 (5.0 g, 1.0 equivalent) and IV-2 (5.3 g, 1.0 equivalent) as raw materials and dissolve them in 80 mL of acetonitrile. Cool the solution to -20°C under nitrogen protection, add cyanotetrazole (977 mg, 1.5 equivalents), and after the reaction is completed at 25°C, extract with 5% sodium bicarbonate solution. After the extract is concentrated to dryness, it is directly purified by silica gel column to obtain heteromorphic nucleoside dimer phosphoramidite I-2 (7.8 g, 81% yield). HPLC purity: 99.15%; MS [M+H] +: 1398.
[0101] Example 3: Synthesis of heteromorphic nucleoside dimer phosphoramidite I-3:
[0102]
[0103] The reaction formula is as follows:
[0104]
[0105] The first step of synthesis of III-3:
[0106] Take II-3 (10g, 1.0 equivalent) and dissolve it in acetonitrile (120mL, 12V), cool it down to 5℃ under nitrogen protection, add 25% concentrated ammonia (2.2g, 3 equivalents) dropwise, and react at 5℃ for 0.5h to complete the reaction. Concentrate and directly purify it on a silica gel column to obtain intermediate III-1 (6.5g, yield 73%). HPLC purity: 99.60%; MS [M+H] +: 884;
[0107] Step 2 Synthesis of I-3:
[0108] Take intermediate III-3 (5.0g, 1.0 equivalent) and IV-3 (4.9g, 1.0 equivalent) as raw materials and dissolve them in 80mL dichloromethane solvent. Cool the solution to -20°C under nitrogen protection, add tetrazole (317mg, 0.8 equivalent), and after the reaction is completed at 25°C, extract with 5% sodium bicarbonate solution. After the extract is concentrated to dryness, it is directly purified by silica gel column to obtain heteromorphic nucleoside dimer phosphoramidite I-1 (7.9g, 85% yield). HPLC purity: 99.03%; MS [M+H] +: 1643.
[0109] In summary, the raw materials II and raw materials IV involved in the method of the present application are commercially available, easy to obtain, and the synthetic route is short, simple to operate, and suitable for large-scale production. In addition, since the phosphoramidite monomer itself has unstable characteristics such as easy oxidation and easy hydrolysis, the present invention adopts ammonia water, which can not only ensure the stability of the phosphoramidite structure but also remove the protecting group, thereby ensuring the perfect synthesis of intermediate III. Intermediate III belongs to a new substance, and there is currently no document or patent to report. At the same time, the heteromorphic nucleoside dimer phosphoramidite I found in the present application belongs to a new substance, and there is currently no document or patent to report. The substance discovery provides a platform significance for the research of oligonucleotide impurity series and the development of new products, and widens the scope of oligonucleotides. Since oligonucleotide drugs belong to gene drugs, impurities will change exponentially during the polymerization process, and purity needs to be strictly controlled. The synthesis method of a heteromorphic nucleoside dimer phosphoramidite of the present application provides ideas for impurity analysis, and provides platform ideas for the analysis and synthesis of other types of dimers, trimers, tetramers, pentamers, etc.
[0110] In the present invention, all features defined in the form of numerical ranges or percentage ranges, such as values, quantities, contents and concentrations, are only for brevity and convenience. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values within the range (including integers and fractions).
[0111] The above-mentioned features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in the specification of this case can be used in combination with any combination form. As long as there is no contradiction in the combination of these features, all possible combinations should be considered to be within the scope of this specification. Each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.
[0112] The embodiments of the present application have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or improvements to the technology in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.
Claims
1. A heteromorphic nucleoside dimer phosphoramidite, characterized in that: The structure of the heteromorphic nucleoside dimer phosphoramidite is shown in Formula I; Formula I: Wherein, R1 and R2 are any one of the protecting groups selected from H, OTBS, OMe, OMOE or F; B1 is any one of adenine base, cytosine base or 5-methylcytosine base; B2 is any one of acetyl-protected adenine base AAc, benzoyl-protected adenine base ABz, isobutyryl-protected guanine base GiBu, thymine base T, acetyl-protected cytosine base CAc, or benzoyl-protected cytosine base CBz.
2. A method for synthesizing a heteromorphic nucleoside dimer phosphoramidite, for synthesizing the heteromorphic nucleoside dimer phosphoramidite according to claim 1, characterized in that: The steps include: Using the compound of formula II as a raw material, removing the acetyl group Ac or the benzoyl group Bz under ammonia conditions to synthesize the intermediate III; Using the intermediate III and the compound of formula IV as raw materials, condensing with a condensing agent to obtain a heteromorphic nucleoside dimer phosphoramidite; Formula II: Intermediate III: Formula IV: The reaction formula is as follows:
3. The method for synthesizing heteromorphic nucleoside dimer phosphoramidite according to claim 2, characterized in that: The method of synthesizing intermediate III by removing acetyl group Ac or benzoyl group Bz from the compound of formula II as a raw material under ammonia conditions comprises: Using the compound of formula II as a raw material, and dissolving it in a first preset volume of a first solvent to obtain a first solution; The first solution is cooled under nitrogen protection, and a first preset amount of concentrated aqueous ammonia is added dropwise to react. After the reaction is completed, it is purified by a silica gel column to obtain an intermediate III.
4. The method for synthesizing heteromorphic nucleoside dimer phosphoramidite according to claim 2, characterized in that: The intermediate III and the compound of formula IV are used as raw materials, and condensed with a condensing agent to obtain a heteromorphic nucleoside dimer phosphoramidite, comprising: Dissolving the intermediate III and the compound of formula IV in a second preset volume of a second solvent to obtain a second solution; The second solution is cooled under nitrogen protection, and a second preset amount of condensing agent is added to react, and after the reaction is completed, extraction is performed using a sodium bicarbonate solution; The extract was concentrated to dryness and then purified by silica gel column to obtain heteromorphic nucleoside dimer phosphoramidite.
5. The method for synthesizing heteromorphic nucleoside dimer phosphoramidite according to claim 4, characterized in that: The second solution is cooled under nitrogen protection, and a second preset amount of condensing agent is added to react, and after the reaction is completed, sodium bicarbonate solution is used for extraction, comprising: The second solution is protected under nitrogen, cooled to -20°C-5°C, and a second preset amount of condensing agent is added to react at a reaction temperature of 25°C; After the reaction was completed, the mixture was extracted with a 5% by mass sodium bicarbonate solution.
6. The method for synthesizing heteromorphic nucleoside dimer phosphoramidites according to claim 5, characterized in that: The condensing agent is any one of tetrazole, ethyl tetrazole, benzyl tetrazole, 5-ethylthio tetrazole or cyanotetrazole, and the second preset amount is 0.5-1.5 equivalents.
7. The method for synthesizing heteromorphic nucleoside dimer phosphoramidites according to claim 3, characterized in that: The first solvent is any one of dichloromethane, tetrahydrofuran or acetonitrile, and the first preset volume is 5-12 times the volume of the compound of formula II.
8. The method for synthesizing heteromorphic nucleoside dimer phosphoramidite according to claim 3, characterized in that: The concentrated ammonia water is 25% ammonia water by mass, and the first preset amount is 3-10 equivalents of the compound of formula II.
9. The method for synthesizing heteromorphic nucleoside dimer phosphoramidites according to claim 4, characterized in that: The equivalent ratio of the intermediate III to the compound of formula IV is 1:
1.
10. The method for synthesizing heteromorphic nucleoside dimer phosphoramidites according to claim 4, characterized in that: The second solvent is any one of dichloromethane, tetrahydrofuran or acetonitrile.
Citation Information
Patent Citations
2'-C-methyluracil nucleoside phosphoramidite monomer and synthetic method thereof
CN110483604A
The invention relates to a one-pot method for synthesizing 3apos; , 3apos; process for dimerization of phosphoramidite
CN117603287A
Phosphoramidite compound, preparation method therefor and use thereof
WO2020010560A1
